meta|Evidence - COVID-19
click on circles to display study description...
ruxolitinib (n=-9) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
ruxolitinib 5mg and 15mg plus standard of care
placebo plus standard of care
COVID-19 severe or critically
double-blind
very preliminary results from a press release. Trial did not meet its primary endpoint due to lack of statistically significant differences for each of the both doses (given that an overall type 1 error risk is needed)
ruxolitinib (n=21) vs. vitamin C (n=21)
randomized controlled trial some concerns about risk of bias
Ruxolitinib
Oral intake of ruxolitinib 5mg twice a day plus standard-of-care.
Vitamin C
100 mg vitamin C twice a day with SoC treatment.
Standard of care in both groups. The SoC treatment included antiviral therapy, supplemental oxygen, noninvasive and invasive ventilation, corticosteroid, antibiotic agents,vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation.
COVID-19 severe or critically
(1) met the diagnostic criteria for COVID-19; (2) 18 years or older and younger than 75 years; (3) severe cases. patients in need of invasive mechanic ventilation at recruitment were ecluded.
Single-blind.
Multicenter, 3 hospitals in China.
Phase II.
powered by vis.js Network